Colchicine treatment for 30 days was evaluated for its anti-inflammatory potential using targeted proteomics in patients with chronic coronary artery disease.
Observational
Does colchicine treatment for 30 days improve anti-inflammatory profiles in patients with chronic coronary artery disease?
This study evaluates the mechanistic anti-inflammatory effects of 30-day colchicine therapy in patients with chronic coronary artery disease using targeted proteomics.
Editorial, see p 1901 I nflammation has a crucial role in the progression of atherosclerosis. COLCOT (Colchicine Cardiovascular Outcome Trial) recently showed cardiovascular benefit of treatment with colchicine. Colchicine may inhibit phagocytosis and neutrophil activity. The effect of colchicine in human atherosclerosis is unclear. We studied the anti-inflammatory potential of colchicine in patients with chronic coronary artery disease by comparing serum samples before and after 30 days of colchicine treatment using targeted proteomics.
Opstal et al. (Mon,) conducted a observational in chronic coronary artery disease. Colchicine vs. Baseline (before treatment) was evaluated on Anti-inflammatory potential assessed via targeted proteomics. Colchicine treatment for 30 days was evaluated for its anti-inflammatory potential using targeted proteomics in patients with chronic coronary artery disease.